PA8508901A1 - Forma de dosificacion de farmaco en capas impulsada por hidrogel - Google Patents
Forma de dosificacion de farmaco en capas impulsada por hidrogelInfo
- Publication number
- PA8508901A1 PA8508901A1 PA20008508901A PA8508901A PA8508901A1 PA 8508901 A1 PA8508901 A1 PA 8508901A1 PA 20008508901 A PA20008508901 A PA 20008508901A PA 8508901 A PA8508901 A PA 8508901A PA 8508901 A1 PA8508901 A1 PA 8508901A1
- Authority
- PA
- Panama
- Prior art keywords
- dosage form
- pharmaco
- hydrogel
- water
- nucleus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
UNA FORMA DE DOSIFICACION DE LIBERACION CONTROLADA PARA SERTRALINA TIENE UN NUCLEO QUE COMPRENDE UNA COMPOSICION QUE CONTIENE SERTRALINA Y UNA COMPOSICION HINCHABLE EN AGUA, EN DONDE LA COMPOSICION HINCHABLE EN AGUA ESTA SITUADA EN UNA REGION SEPARADA DENTRO DEL NUCLEO. UN REVESTIMIENTO EN TORNO AL NUCLEO ES PERMEABLE AL AGUA, INSOLUBLE EN AGUA Y TIENE AL MENOS UNA ABERTURA DE SUMINISTRO A TRAVES DEL MISMO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17210899P | 1999-12-23 | 1999-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8508901A1 true PA8508901A1 (es) | 2003-12-10 |
Family
ID=22626396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20008508901A PA8508901A1 (es) | 1999-12-23 | 2000-12-22 | Forma de dosificacion de farmaco en capas impulsada por hidrogel |
Country Status (15)
Country | Link |
---|---|
US (1) | US6899896B2 (es) |
EP (1) | EP1239839A2 (es) |
JP (1) | JP2003518487A (es) |
AR (1) | AR027066A1 (es) |
AU (1) | AU1724301A (es) |
BR (1) | BR0016707A (es) |
CA (1) | CA2395231C (es) |
CO (1) | CO5271728A1 (es) |
GT (1) | GT200000220A (es) |
MX (1) | MXPA02006335A (es) |
PA (1) | PA8508901A1 (es) |
PE (1) | PE20010983A1 (es) |
TN (1) | TNSN00251A1 (es) |
UY (1) | UY26493A1 (es) |
WO (1) | WO2001047498A2 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60038698T2 (de) * | 1999-12-23 | 2009-05-07 | Pfizer Products Inc., Groton | Hydrogel-gesteuerte dosierungsform |
WO2003000226A2 (en) * | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions containing polymer and drug assemblies |
ATE444060T1 (de) | 2001-06-22 | 2009-10-15 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren |
US20040146559A1 (en) * | 2002-09-28 | 2004-07-29 | Sowden Harry S. | Dosage forms having an inner core and outer shell with different shapes |
BR0212950A (pt) * | 2001-09-28 | 2004-10-26 | Mcneil Ppc Inc | Formas de dosagens compósitas tendo uma porção inserida |
BR0307344A (pt) | 2002-02-01 | 2004-12-14 | Pfizer Prod Inc | Composições farmacêuticas de dispersões amorfas de fármacos e materiais formadores de microfase lipofìlica |
GB0203296D0 (en) | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
US8637512B2 (en) | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
US7785627B2 (en) | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US8084058B2 (en) | 2002-09-20 | 2011-12-27 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US7959946B2 (en) | 2002-09-20 | 2011-06-14 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US9060941B2 (en) | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
EP2604266A1 (en) * | 2002-09-20 | 2013-06-19 | Andrx Labs Llc | Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US20040081695A1 (en) * | 2002-09-28 | 2004-04-29 | Sowden Harry S | Dosage forms having an inner core and an outer shell |
US20060167113A1 (en) * | 2002-11-07 | 2006-07-27 | Torrent Pharmaceuticals Ltd. | Process for preparation of polymorphic form of sertraline hydrochloride |
CA2415154C (en) * | 2002-12-24 | 2009-06-16 | Biovail Laboratories Inc. | Modified release formulations of selective serotonin re-uptake inhibitors |
EP1653927B1 (en) | 2003-08-04 | 2012-01-11 | Bend Research, Inc. | Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials |
KR20070009671A (ko) * | 2004-05-06 | 2007-01-18 | 사이덱스 인크 | 세르트랄린 및 술포알킬 에테르 시클로덱스트린을 함유하는맛 마스킹된 제제 |
WO2006072878A1 (en) * | 2005-01-07 | 2006-07-13 | Ranbaxy Laboratories Limited | Oral dosage forms of sertraline having controlled particle size and processes for their preparation |
US20060233882A1 (en) * | 2005-04-15 | 2006-10-19 | Sowden Harry S | Osmotic dosage form |
US20060239956A1 (en) * | 2005-04-26 | 2006-10-26 | Lulu Henson | Preparation and use of hydrogels |
JP2009514884A (ja) * | 2005-11-04 | 2009-04-09 | イーストマン ケミカル カンパニー | 難溶性医薬活性剤の投与のためのカルボキシアルキルセルロースエステル |
WO2007057762A2 (en) * | 2005-11-16 | 2007-05-24 | Pfizer Limited | Osmotic bi-layer tablet |
CN100563637C (zh) * | 2006-10-13 | 2009-12-02 | 北京红林制药有限公司 | 一种控释给药的药芯组合物和控释制剂及其制备方法 |
ECSP077628A (es) | 2007-05-03 | 2008-12-30 | Smithkline Beechman Corp | Nueva composición farmacéutica |
PT2506842E (pt) | 2009-12-04 | 2015-03-10 | Sunovion Pharmaceuticals Inc | Formulações, sais e polimorfos de transnorsertralina e suas utilizações |
WO2011078993A1 (en) | 2009-12-21 | 2011-06-30 | Aptapharma, Inc. | Functionally-coated multilayer tablets |
WO2016020936A2 (en) * | 2014-07-21 | 2016-02-11 | Patel Jayendrakumar Dasharathlal | A novel oral gastroretentive pharmaceutical dosage form |
JP6455293B2 (ja) * | 2015-04-21 | 2019-01-23 | ニプロ株式会社 | セルトラリン及び/又はその薬学上許容しうる塩を含む製剤 |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4536518A (en) | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US5366738A (en) | 1982-07-29 | 1994-11-22 | Merck & Co., Inc. | Controlled release drug dispersion delivery device |
US5082668A (en) | 1983-05-11 | 1992-01-21 | Alza Corporation | Controlled-release system with constant pushing source |
US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
USRE33994E (en) | 1983-08-16 | 1992-07-14 | Burroughs Wellcome Co. | Pharmaceutical delivery system |
US4968507A (en) | 1984-06-20 | 1990-11-06 | Merck & Co., Inc. | Controlled porosity osmotic pump |
US4609374A (en) | 1985-04-22 | 1986-09-02 | Alza Corporation | Osmotic device comprising means for governing initial time of agent release therefrom |
US4624847A (en) | 1985-04-22 | 1986-11-25 | Alza Corporation | Drug delivery device for programmed delivery of beneficial drug |
GB8518301D0 (en) | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
US4865598A (en) | 1985-08-16 | 1989-09-12 | Alza Corporation | Dispensing system for administering beneficial agent |
GB8521494D0 (en) | 1985-08-29 | 1985-10-02 | Zyma Sa | Controlled release tablet |
IT1188212B (it) | 1985-12-20 | 1988-01-07 | Paolo Colombo | Sistema per il rilascio a velocita' controllata di sostanze attive |
US4755180A (en) | 1986-06-16 | 1988-07-05 | Alza Corporation | Dosage form comprising solubility regulating member |
EP0277092B1 (de) | 1987-01-14 | 1992-01-29 | Ciba-Geigy Ag | Therapeutisches System für schwerlösliche Wirkstoffe |
US4915954A (en) | 1987-09-03 | 1990-04-10 | Alza Corporation | Dosage form for delivering a drug at two different rates |
US4946687A (en) | 1987-10-02 | 1990-08-07 | Alza Corporation | Dosage form for treating cardiovascular diseases |
US4971998A (en) | 1987-10-22 | 1990-11-20 | Massachusetts Institute Of Technology | Methods for treating the premenstrual or late luteal phase syndrome |
US4837111A (en) | 1988-03-21 | 1989-06-06 | Alza Corporation | Dosage form for dispensing drug for human therapy |
FI101344B1 (fi) | 1988-03-31 | 1998-06-15 | Tanabe Seiyaku Co | Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseuttisesti aktiivista ainetta |
US5030456A (en) | 1988-11-07 | 1991-07-09 | Alza Corporation | Dosage form for treating cardiovascular diseases |
US5034229A (en) | 1988-12-13 | 1991-07-23 | Alza Corporation | Dispenser for increasing feed conversion of hog |
IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
DD295760A5 (de) | 1989-01-31 | 1991-11-14 | Martin-Luther-Universitaet Halle Wittenberg,De | Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung |
US4981870A (en) | 1989-03-07 | 1991-01-01 | Pfizer Inc. | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants |
US5019396A (en) | 1989-05-12 | 1991-05-28 | Alza Corporation | Delivery dispenser for treating cardiac arrhythmias |
US5126142A (en) | 1989-07-18 | 1992-06-30 | Alza Corporation | Dispenser comprising ionophore |
US5273752A (en) | 1989-07-18 | 1993-12-28 | Alza Corporation | Controlled release dispenser comprising beneficial agent |
US5130338A (en) | 1989-08-30 | 1992-07-14 | Pfizer Inc. | Method of treating chemical dependencies using sertraline |
US4940731A (en) | 1989-08-30 | 1990-07-10 | Pfizer Inc. | Method of treating premature ejaculation using sertraline |
US5035897A (en) | 1989-09-05 | 1991-07-30 | Alza Corporation | Dosage form for delivering soluble or insoluble drugs |
US5091190A (en) | 1989-09-05 | 1992-02-25 | Alza Corporation | Delivery system for administration blood-glucose lowering drug |
US4962128A (en) | 1989-11-02 | 1990-10-09 | Pfizer Inc. | Method of treating anxiety-related disorders using sertraline |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5200197A (en) | 1989-11-16 | 1993-04-06 | Alza Corporation | Contraceptive pill |
US5178866A (en) | 1990-03-23 | 1993-01-12 | Alza Corporation | Dosage form for delivering drug to the intestine |
US5192550A (en) | 1990-05-07 | 1993-03-09 | Alza Corporation | Dosage form for treating central nervous system disorders |
US5221536A (en) | 1990-05-07 | 1993-06-22 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
US5190763A (en) | 1990-05-07 | 1993-03-02 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
US5128145A (en) | 1990-06-13 | 1992-07-07 | Alza Corporation | Dosage form for Parkinson's disease, spasticity and muscle spasms |
US5057321A (en) | 1990-06-13 | 1991-10-15 | Alza Corporation | Dosage form comprising drug and maltodextrin |
US5156850A (en) | 1990-08-31 | 1992-10-20 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
ATE106015T1 (de) | 1990-09-28 | 1994-06-15 | Pfizer | Wirkstoffabgabevorrichtung die ein hydrophobisches mittel enthält. |
US5284662A (en) | 1990-10-01 | 1994-02-08 | Ciba-Geigy Corp. | Oral osmotic system for slightly soluble active agents |
US5208037A (en) | 1991-04-22 | 1993-05-04 | Alza Corporation | Dosage forms comprising polymers comprising different molecular weights |
US5160744A (en) | 1991-06-27 | 1992-11-03 | Alza Corporation | Verapmil therapy |
US5178867A (en) | 1991-08-19 | 1993-01-12 | Alza Corporation | Dosage form for delivering drug in short-time period |
AU2867492A (en) | 1991-10-10 | 1993-05-03 | Alza Corporation | Osmotic drug delivery devices with hydrophobic wall materials |
US5183942A (en) | 1991-11-05 | 1993-02-02 | The Scripps Research Institute | Ten-membered ring enediynediols and enediynediones having DNA cleaving properties |
US5543154A (en) | 1991-12-27 | 1996-08-06 | Merck & Co., Inc. | Controlled release nifedipine delivery device |
US5294770A (en) | 1992-01-14 | 1994-03-15 | Alza Corporation | Laser tablet treatment system with dual access to tablet |
US5246711A (en) | 1992-02-27 | 1993-09-21 | Alza Corporation | Dosage form for treating dysthymia |
US5688518A (en) | 1992-02-27 | 1997-11-18 | Alza Corporation | Antidepressive therapy |
US5185158A (en) | 1992-02-27 | 1993-02-09 | Alza Corporation | Dosage form comprising succinimide drug for treating depressive disorders and composition comprising same |
US5246710A (en) | 1992-02-27 | 1993-09-21 | Alza Corporation | Dosage form for treating cyclothymia |
US5609885A (en) | 1992-09-15 | 1997-03-11 | Alza Corporation | Osmotic membrane and delivery device |
US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
US5358721A (en) | 1992-12-04 | 1994-10-25 | Alza Corporation | Antiviral therapy |
ATE195252T1 (de) | 1993-04-23 | 2000-08-15 | Novartis Erfind Verwalt Gmbh | Wirkstoffabgabevorrichtung mit gesteuerter freigabe |
US6287598B1 (en) | 1993-05-28 | 2001-09-11 | Alza Corporation | Method for providing sustained antiepileptic therapy |
US5455046A (en) | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
HU213407B (en) | 1993-12-09 | 1997-06-30 | Egyt Gyogyszervegyeszeti Gyar | Process for producing tablet with diffusive-osmotic release |
US5458888A (en) | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
US5458887A (en) | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
ZA953078B (en) | 1994-04-28 | 1996-01-05 | Alza Corp | Effective therapy for epilepsies |
CZ292360B6 (cs) | 1994-05-06 | 2003-09-17 | Pfizer Inc. | Dávkovací forma s řízeným uvolňováním obsahující azithromycin a způsob její výroby |
US5698224A (en) | 1994-06-27 | 1997-12-16 | Alza Corporation | Tacrine therapy |
US5529787A (en) | 1994-07-07 | 1996-06-25 | Alza Corporation | Hydromorphone therapy |
US5718700A (en) | 1994-09-20 | 1998-02-17 | Alza Corporation | Exit means in dosage form |
US5658474A (en) | 1994-12-16 | 1997-08-19 | Alza Corporation | Method and apparatus for forming dispenser delivery ports |
US5607696A (en) | 1995-02-10 | 1997-03-04 | Alza Corporation | Osmotic membrane and delivery device |
US5736159A (en) | 1995-04-28 | 1998-04-07 | Andrx Pharmaceuticals, Inc. | Controlled release formulation for water insoluble drugs in which a passageway is formed in situ |
US5654005A (en) | 1995-06-07 | 1997-08-05 | Andrx Pharmaceuticals, Inc. | Controlled release formulation having a preformed passageway |
US5840332A (en) | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
ZA97976B (en) * | 1996-04-05 | 1997-08-18 | Alza Corp | Uniform drug delivery theraphy. |
US5837379A (en) | 1997-01-31 | 1998-11-17 | Andrx Pharmaceuticals, Inc. | Once daily pharmaceutical tablet having a unitary core |
WO1998053802A1 (en) | 1997-05-30 | 1998-12-03 | Laboratorios Phoenix U.S.A., Inc. | Multi-layered osmotic device |
AU739261B2 (en) * | 1997-07-01 | 2001-10-11 | Pfizer Inc. | Sertraline salts and sustained-release dosage forms of sertraline |
ATE433318T1 (de) * | 1999-02-10 | 2009-06-15 | Pfizer Prod Inc | Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten |
-
2000
- 2000-12-13 MX MXPA02006335A patent/MXPA02006335A/es active IP Right Grant
- 2000-12-13 EP EP00979866A patent/EP1239839A2/en not_active Withdrawn
- 2000-12-13 JP JP2001548093A patent/JP2003518487A/ja not_active Withdrawn
- 2000-12-13 CA CA002395231A patent/CA2395231C/en not_active Expired - Fee Related
- 2000-12-13 AU AU17243/01A patent/AU1724301A/en not_active Abandoned
- 2000-12-13 BR BR0016707-0A patent/BR0016707A/pt not_active IP Right Cessation
- 2000-12-13 WO PCT/IB2000/001871 patent/WO2001047498A2/en not_active Application Discontinuation
- 2000-12-20 US US09/745,096 patent/US6899896B2/en not_active Expired - Fee Related
- 2000-12-20 UY UY26493A patent/UY26493A1/es not_active Application Discontinuation
- 2000-12-21 AR ARP000106853A patent/AR027066A1/es unknown
- 2000-12-21 GT GT200000220A patent/GT200000220A/es unknown
- 2000-12-21 PE PE2000001381A patent/PE20010983A1/es not_active Application Discontinuation
- 2000-12-21 CO CO00097187A patent/CO5271728A1/es not_active Application Discontinuation
- 2000-12-22 PA PA20008508901A patent/PA8508901A1/es unknown
- 2000-12-22 TN TNTNSN00251A patent/TNSN00251A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
AU1724301A (en) | 2001-07-09 |
TNSN00251A1 (fr) | 2002-05-30 |
MXPA02006335A (es) | 2002-12-13 |
UY26493A1 (es) | 2001-07-31 |
CO5271728A1 (es) | 2003-04-30 |
WO2001047498A3 (en) | 2001-11-15 |
GT200000220A (es) | 2002-06-14 |
JP2003518487A (ja) | 2003-06-10 |
WO2001047498A2 (en) | 2001-07-05 |
EP1239839A2 (en) | 2002-09-18 |
CA2395231C (en) | 2006-08-15 |
BR0016707A (pt) | 2002-09-03 |
PE20010983A1 (es) | 2001-10-01 |
US20010044474A1 (en) | 2001-11-22 |
CA2395231A1 (en) | 2001-07-05 |
AR027066A1 (es) | 2003-03-12 |
US6899896B2 (en) | 2005-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8508901A1 (es) | Forma de dosificacion de farmaco en capas impulsada por hidrogel | |
SV2002000586A (es) | Formula de dosificacion de la droga accionada por hidrogel ref. pc11095/700006/b | |
PA8509001A1 (es) | Forma de dosificacion de farmacos accionada por un hidrogel | |
AR005009A1 (es) | Monohidrato del cdch, procedimiento para su produccion , composiciones antibacteriales que lo contienen, uso del monohidrato del cdch para la manufactura de medicamentos. | |
CO4900058A1 (es) | Terapia de combinacion para el tratamiento de psicosis | |
AR002720A1 (es) | Proceso para preparar una composición oral sólida de olanzapina con subrecubrimiento de polímero y recubrimiento coloreado | |
SV2002000520A (es) | Derivados de pirazol ref. pcs10927aajr/bb | |
ES2141713T3 (es) | Formulaciones estabilizadas de liberacion controlada recubiertas de una capa de polimero acrilico. | |
BR9801455A (pt) | Processo e tablete de alvejamento revestido | |
ES2155696T3 (es) | Material compuesto permeable al vapor de agua. | |
ES2160897T3 (es) | Pirazoles como inhibidores de la secretora fosfolipasa a2 humana no pancreatica. | |
DE69531790D1 (de) | Duschaufsatz | |
EE05281B1 (et) | Fenofibraadi ja koensüüm Q10 kombinatsioon endoteeli düsfunktsiooni ravimiseks | |
CL2007001752A1 (es) | Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral. | |
AR033325A1 (es) | Composicion que comprende una carnitina y glutationa , util para incrementar la absorcion de la glutationa y sinergizar sus efectos, un complemento dietario, medicamento, la utilizacion de una composicion de combinacion para preparar un complemento dietario o un medicamento | |
AR025052A1 (es) | Derivados de 2-dialquilaminoalquilbifenilo sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estoscompuestos para la preparacion de medicamentos. | |
ES2191987T3 (es) | Formas de dosificacion de ribavirina solidas, administrables oralmente, y procedimiento de fabricacion. | |
NO20012985D0 (no) | Anvendelse av apomorfin i fremstilling av et medikament for behandling av organisk erektil dysfunksjon i hanner | |
PE8298A1 (es) | Tabletas exentas de aglutinante que contienen tramadol o una sal de tramadol para administracion oral | |
CO4910140A1 (es) | Intermediarios y proceso para preparar olanzapina | |
TR200400228T4 (tr) | Psöryazinin tedavisinde kullanılacak maddeler | |
ES2154064T3 (es) | Recipiente provisto de un pincel para un adhesivo de cianoacrilato. | |
TR200001040T2 (tr) | Kaşıntıyı önleme etkisi için bileşiklerin yeni bir kullanımı | |
AR037846A1 (es) | Un articulo absorbente para absorber desechos corporales y un metodo para inhibir la produccion de amoniaco de la orina mantenida adyacente a la piel del usuario por dicho articulo. | |
PA8523101A1 (es) | Composicion de eletriptan en forma de particulas |